A Japan-based biotechnology firm has progressed its stem cell therapeutic protocol to clinical trial stages, focusing on diabetes treatment mechanisms. The development showcases potential integration opportunities between traditional biotech research and decentralized science (DeSci) funding models gaining traction in Web3 healthcare initiatives.
Source: Nikkei Asia Read Full Story